AOD News and Press, Aberdeen Total Dynamic Dividend Fund From 06/03/25

2025-06-03 09:00:00 ET Summary After a very strong 2024, it was a challenging start to the new year with the Fund contracting by 6.58% in US dollar terms, underperforming the benchmark by 363 basis points in NAV terms. Some of the key detractors this quarter had been among the bes...

2025-06-03 08:20:00 ET Summary The equity portion of the Fund rose (gross of fees) but underperformed its benchmark over the quarter. The top three detractors over the quarter were Novo Nordisk, uniQure and Teva Pharmaceutical Industries. The top three positive contributors we...

2025-06-03 08:05:00 ET Summary The abrdn Ultra Short Municipal Income Fund returned 0.75% for the first quarter, underperforming the 1.05% return of its benchmark, the Bloomberg Barclays Municipal Bond 1 Year (1-2) Index. During the quarter, the Fund’s exposures to other re...

2025-06-03 08:00:00 ET Summary The Fund fell (gross of fees) but outperformed the Russell 2000 Index. At the stock level, Corcept Therapeutics’ shares outperformed after the company’s key drug achieved positive study results for the treatment of a new condition, sign...

2025-06-03 07:20:00 ET Summary The abrdn Total Dynamic Dividend Fund outperformed its benchmark over the three-month period ending 30 April 2025 due to stock selection and, to a lesser extent, sector allocation. Global equity markets ended lower over the period, weighed down by mo...

2025-06-03 07:00:00 ET Summary The abrdn Short Duration High Yield Municipal Fund returned 0.47% for the first quarter, underperforming the 0.78% return of its benchmark, the S&P Municipal Bond Short Intermediate Index. During the quarter, the Fund’s exposure to student...

2025-06-03 06:50:00 ET Summary The abrdn National Municipal Income Fund returned -1.40% for the first quarter on a net asset value basis, underperforming the -0.22% return of its benchmark, the Bloomberg Municipal Bond Index. The Fund’s exposure to education revenue bonds, ...

2025-06-02 05:00:45 ET We’ve got a rare “delayed reaction” income play on our hands right now. Thanks to the April stock-market plunge, we can now pick up 12%+ dividends at attractive discounts. But I don’t expect this opportunity to last very long. I kno...

2025-05-31 00:20:00 ET Summary The equity portion of the Fund fell (gross of fees) and underperformed its benchmark, the NASDAQ Biotechnology Index. During the first quarter of 2025, we made several changes to the portfolio. With Donald Trump securing his second term, uncertai...

2025-05-30 22:50:00 ET Summary The Fund underperformed the benchmark over the quarter due to both sector allocation and stock selection. We made two new initiations and sold one holding during the quarter. Macroeconomic volatility remains elevated, as US trade policy continues...